China sides with Emmanulle Charpentier and Jennifer Doudna in CRISPR patent war
By Sarah Buhr,
Tech Crunch
| 06. 19. 2017
Continuing the patent dispute internationally, China has now given the Charpentier/Doudna side a patent to edit genes in the country.
CRISPR pioneers Emmanuelle Charpentier and Jennifer Doudna lost a patent case to the Broad Insititute earlier this year when the court determined the Broad Insititute had an application markedly different than Charpentier’s and Doudna’s overall patent. UC Berkeley and Charpentier’s team are fighting that decision in the U.S.
Undaunted, Doudna told TechCrunch at the time that outcome was a positive. “I’m actually delighted to know the claims of our original patent have been allowed by the patent examiner and can now move forward towards issuance,” she said. “The Broad Institute’s patent is for green tennis balls but the patent we will have is for all tennis balls.”
What remains unclear is how U.S. companies wishing to license the patented technology will need to deal with both the broader sweeping Charpentier and Broad patent, as well as the patent granted to the Broad Institute.
That’s a different story across the pond in Europe and the United Kingdom, which both granted patents to...
Related Articles
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...
By Gina Kolata, The New York Times | 09.22.2025
On May 26, Tracy Atteberry checked in to the hospital at the National Institutes of Health in Bethesda, Md. The 57-year-old has an ultrarare inherited disease that hobbles his immune system so that the most innocuous of germs could kill...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...